1 / 78

Update on Quality Pneumonia Care

Update on Quality Pneumonia Care. Tosha Wetterneck, MD Primary Care Conference August 18, 2004. I do not have any financial disclosures or conflicts of interest to disclose. Are physicians aware of and using pneumonia guidelines?. Answer: We can do better Switzer, et al. JGIM 2003

yoko
Télécharger la présentation

Update on Quality Pneumonia Care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on Quality Pneumonia Care Tosha Wetterneck, MD Primary Care Conference August 18, 2004

  2. I do not have any financial disclosures or conflicts of interest to disclose.

  3. Are physicians aware of and using pneumonia guidelines? • Answer: We can do better • Switzer, et al. JGIM 2003 • Surveyed 621 MD’s at 7 hospitals in PA (response rate 56%) • >70% familiar with guidelines (ATS/local) • 30-60% of those reported using guideline • Guidelines / Critical pathways for pneumonia can decrease LOS, cost and mortality* *Marrie, JAMA 2000; Dean, Am J Med 2001

  4. Objectives • Raise awareness of Community Acquired Pneumonia (CAP) guidelines • Review quality care for Community Acquired Pneumonia (CAP) • Understand the latest in CAP care • Antibiotic Selection • Diagnostic testing • Prevention • Learn about CAP Quality Initiatives at UWHC

  5. Conclusions • CAP care is an important, publicly reported quality indicator • JCAHO and others monitor: • Blood Culture Use (prior to antibiotics) • Antibiotic Timing (within 4 hours of arrival) • Antibiotic Selection (new) • Smoking Cessation Counseling • Pneumococcal Screening & Vaccination • Influenza Screening & Vaccination (new)

  6. Conclusions 2 • Use UWHC guidelines for antibiotic selection (based on 2003 IDSA guidelines) • Use patient setting, comorbidities, allergies and recent antibiotic use to guide selection • Outpatient: • Healthy: macrolide or doxycycline • Comorbidities: Resp fluoroquinolone (FQ) or Ketolide or Macrolide + Beta-lactam • Inpatient: • Non ICU: Cephalosporin + Macrolide or Resp FQ • ICU: must use 2 drugs, assess for pseudomonas risk

  7. Conclusions 3 • Nursing home: • Advanced macrolide + amox-clavulanate or Respiratory fluoroquinolone or Ketolide • Recent antibiotic therapy (3 months) confers risk for resistance and a different antibiotic class should be chosen • Drug resistant pneumococcus is a growing problem • Save the fluoroquinolones (judicious use)

  8. Conclusions 4 • Be aware of new antibiotics (ketolides), drug interactions and short course therapy • An ounce of prevention… • Patient Immunization: pneumococcal and influenza • Health Care Worker Influenza immunization • Smoking cessation counseling

  9. Pneumonia is a growing health problem • 4-5 million cases of CAP yearly • 1.7 million hospitalizations annually • 30-40 admissions per month at UWHC • 7th leading cause of death in US • $10 billion dollars spent yearly on CAP • Inpatient: $5700/case, Outpatient: $300 • $100 million on antimicrobials National Vital Statistics Reports, 2001 data; AHRQ Research in Action #7

  10. Gaps exist in quality of care • JCAHO Performance Measures • Agenda for Change, 1987 • Core Measures • Developed 1999-2000; Piloted 2001, 16 hospitals • Evidence-based quality indicators • Variety of stakeholders involved • Four Core Measures Sets selected (CAP, CHF, AMI, L&D) • Data collection at UWHC since 3rd Q 2003

  11. 7 CAP Quality Indicators • Oxygenation assessment • Blood Culture Use (prior to antibiotics) • Antibiotic Timing (within 4 hours of arrival) • Antibiotic Selection (new) • Smoking Cessation Counseling • Pneumococcal Screening & Vaccination • Influenza Screening & Vaccination (new)

  12. Quality Indicators and Outcomes • Early antibiotic therapy: decreased LOS and mortality • Blood cultures in first 24 hours: decreased mortality • Appropriate antibiotics: decreased LOS and mortality • Early IV to po antibiotic switch: decreased LOS and cost • Influenza vaccination: decreased mortality Meehan, JAMA 1997; Battleman, Arch Int Med 2002; Gleason, Arch Int Med 1999; Ramirez, Arch Int Med 1999

  13. CAP - Oxygen Assessment Source: University HealthSystem Consortium JCAHO Core Measures, CY2003Q2, CY2003Q3, CY2003Q4, CY2004Q1

  14. CAP – Blood Cultures (prior to Antibiotics) Source: University HealthSystem Consortium JCAHO Core Measures, CY2003Q2, CY2003Q3, CY2003Q4, CY2004Q1

  15. CAP - Antibiotic Timing, mean time

  16. CAP - Antibiotic Timing, median time

  17. CAP - Smoking Cessation Counseling

  18. CAP - Pneumococcal Screening/Vaccine

  19. Everyone wants this data… • CMS voluntary reporting (2003) • Public data released Feb 04 • Tied to reimbursement • JCAHO public data reporting (July 2004) • WHA public reporting (March 2004) • WI Collaborative for Healthcare Quality • UWHC Quality and Safety Report • Business report: July 2004 • Consumer report: Sept 2004

  20. Remainder of talk… • Understand the latest in CAP care • Antibiotic Selection • Diagnostic testing • Prevention • Learn about CAP Quality Initiatives at UWHC

  21. Etiology of CAP • Causative agent known in less than half of patients • Bacterial: 40-60%, • S pneumoniae (15-35%), H flu, Moraxella • Atypical pathogens: 10-30% • Mycoplasma, Chlamydia, Legionella • Other agents: 5%-25% • Viruses, PCP, MTB • Unknown: 30-60%, two agents: 15%

  22. IDSA 2003 Guidelines • Latest guidelines for CAP treatment • Update 2000 guidelines • UWHC guidelines based heavily on IDSA guidelines + latest evidence

  23. Antibiotic selection guidelines • Setting: • Outpatient vs. Inpatient, non-ICU vs ICU • Patient factors: • Comorbidities: COPD, diabetes, renal disease, CHF or malignancy • Recent antibiotic therapy: within past 3 months= choose different antibiotic class • Pseudomonal risk: severe structural lung disease, recent Abx or stay in hospital

  24. Please forgive my use of unapproved abbreviations in the remainder of the talk • q = every • b.i.d. = twice daily • t.i.d. = three times daily • q.i.d. = four times daily

  25. Outpatient treatment- Previously healthy patient, no recent antimicrobial therapy* • Preferred treatment: • Macrolide or doxycycline • Specific antimicrobial choices: • Azithromycin, one Z pak as directed OR Clarithromycin 500mg b.i.d. x 10 days OR Erythromycin for 10-14 days • Doxycycline 100mg b.i.d. x 10-14 days * Patients usually young, non-smoking

  26. Outpatient treatment- Previously healthy patient, +recent antimicrobial therapy* • Preferred treatment: • Advanced macrolide + high dose amoxicillin • Advanced macrolide + amox-clavulanate • Respiratory fluoroquinolone • Ketolide * Risk factor for resistant pneumococcus

  27. Outpatient treatment- Previously healthy patient, +recent antimicrobial therapy • Specific antimicrobial choices: • Azithromycin, one Z pak as directed OR Clarithromycin 500mg b.i.d. x 10 days + Amoxicillin 1g t.i.d. OR Amoxicillin-clavulanate XR* 2 tablets b.i.d. x 10 days • Moxifloxacin 400mg daily x 10 days OR Gatifloxacin 400mg daily x 10 days OR Levofloxacin 750mg daily x 5 days • Telithromycin 800mg daily x 7-10 days * Augmentin XR is 1000mg amoxicillin and 125mg clavulanate

  28. Outpatient treatment- Comorbidities*, no recent antimicrobial therapy • Preferred treatment: • Advanced macrolide • Respiratory fluoroquinolone • Ketolide *COPD, diabetes, renal disease, CHF or malignancy

  29. Outpatient treatment- Comorbidities, No recent antimicrobial therapy • Specific antimicrobial choices: • Azithromycin, one Z pak as directed OR Clarithromycin 500mg b.i.d. x 10 days • Moxifloxacin 400mg daily x 10 days OR Gatifloxacin 400mg daily x 10 days OR Levofloxacin 750mg daily x 5 days • Telithromycin 800mg daily x 7-10 days

  30. Outpatient treatment- Comorbidities, +Recent antimicrobial therapy • Preferred treatment: • Advanced macrolide + beta-lactam • Respiratory fluoroquinolone • Ketolide

  31. Outpatient treatment- Comorbidities, +Recent antimicrobial therapy • Specific antimicrobial choices: • Azithromycin, one Z pak as directed ORClarithromycin 500mg b.i.d. x 10 days + Amoxicillin 1g t.i.d. x OR Amoxicillin-clavulanate XR* 2 tablets b.i.d. OR Cefpodoxime 200mg b.i.d. x 10 days • Moxifloxacin 400mg daily x 10 days OR Gatifloxacin 400mg daily x 10 days OR Levofloxacin 750mg daily x 5 days • Telithromycin 800mg daily x 7-10 days * Augmentin XR is 1000mg amoxicillin and 125mg clavulanate

  32. Outpatient treatment- Suspected aspiration • Preferred treatment: • Amoxicillin-clavulanate or Clindamycin • Specific antimicrobial choices: • Amoxicillin-clavulanate 875/125mg b.i.d. x 10 days • Clindamycin 300mg q.i.d. x 10 days

  33. Outpatient treatment- Influenza with bacterial superinfection • Preferred treatment: • Beta-lactam • Respiratory Fluoroquinolone

  34. Outpatient treatment- Influenza with bacterial superinfection • Specific antimicrobial choices: • Amoxicillin 1 g t.i.d. OR Amoxicillin-clavulanate XR* 2 tablets b.i.d. OR Cefpodoxime 200mg b.i.d. x 10 days • Moxifloxacin 400mg daily x 10 days OR Gatifloxacin 400mg daily x 10 days OR Levofloxacin 750mg daily x 5 days * Augmentin XR is 1000mg amoxicillin and 125mg clavulanate and may not be on all formularies

  35. Inpatient treatment- Non-ICU, No recent antimicrobial therapy • Preferred treatment: • Advanced macrolide + beta-lactam • Respiratory fluoroquinolone • Specific antimicrobial choices: • Ceftriaxone 1 g IV daily + Azithromycin 500 mg IV daily • Moxifloxacin 400mg IV daily

  36. Inpatient treatment- Non-ICU, +Recent antimicrobial therapy • Preferred treatment: • Sane as above EXCEPT choose a different antibiotic than previous therapy • Specific antimicrobial choices: • Ceftriaxone 1 g IV daily + Azithromycin 500 mg IV daily • Moxifloxacin 400mg IV daily

  37. Inpatient treatment- ICU, No pseudomonal risk* • Preferred treatment: • Beta-lactam + Advanced macrolide OR Respiratory fluoroquinolone • Specific antimicrobial choices: • Ceftriaxone 1 g IV daily + Azithromycin 500 mg IV daily OR Moxifloxacin 400mg IV daily *Pseudomonal risk: severe structural lung disease, recent Abx or stay in hospital

  38. Inpatient treatment- ICU, No pseudomonal risk, +Beta lactam allergy • Preferred treatment: • Respiratory fluoroquinolone +/- Clindamycin • Specific antimicrobial choices: • Moxifloxacin 400mg IV daily +/- Clindamycin 600-900mg IV every 6 hours

  39. Inpatient treatment- ICU, +Pseudomonal risk* • Preferred treatment: • Antipseudomonal agent + Ciprofloxacin • Antipseudomonal agent + Aminoglycoside + Respiratory fluoroquinolone OR Advanced macrolide *Pseudomonal risk: severe structural lung disease, recent Abx or stay in hospital

  40. Inpatient treatment- ICU, +Pseudomonal risk • Specific antimicrobial choices: • Piperacillin 4g IV q6h OR Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Imipenem 500mg q6h + Ciprofloxacin 400mg IV q8h • Piperacillin 4g IV q6h OR Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Imipenem 500mg q6h + Gentamicin OR Tobramycin OR Amikacin + Moxifloxacin 400mg IV daily OR Azithromycin 500 mg IV daily

  41. Inpatient treatment- ICU, +Pseudomonal risk +Beta-lactam allergy • Preferred treatment: • Aztreonam + Antipseudomonal agent +/- Aminoglycoside • Specific antimicrobial choices: • Aztreonam 2g q8h + Ciprofloxacin 400mg IV q8h OR Levofloxacin 750mg IV daily +/- Gentamicin OR Tobramycin OR Amikacin

  42. Nursing Home Treatment • Preferred treatment: • Advanced macrolide + amox-clavulanate • Respiratory fluoroquinolone • Ketolide

  43. Nursing Home Treatment • Specific antimicrobial choices: • Azithromycin, one Z pak as directed OR Clarithromycin 500mg b.i.d. x 10 days + Amoxicillin-clavulanate XR 2 tablets b.i.d. x 10 days • Moxifloxacin 400mg daily x 10 days OR Gatifloxacin 400mg daily x 10 days OR Levofloxacin 750mg daily x 5 days • Telithromycin 800mg daily x 7-10 days

  44. Caveats to Antibiotic Therapy • Drug resistant pneumococci • Monotherapy vs. dual therapy • Fluoroquinolone therapy • Ketolides • QT prolongation side effects • Short course therapy

  45. S. Pneumoniae : Growing Antimicrobial resistance in US • PCN resistance growing • 39% of 2000-01 US isolates have high or intermediate level resistance • 3-4% increase yearly from 1995 • ¾ PCN resistant also macrolide resistant • Erythromycin resistance: 31% • Cefuroxime resistance: 30% • Fluoroquinolone resistance: 1% Doern, J Inf 2004

  46. Drug Resistant Pneumococci • Risk Factors: • Age > 65 • Beta-lactam therapy last 3 months* • Alcoholism • Immunosuppression (including steroids)* • Exposure to child in day care • Multiple comorbidities* *Shown in multiple studies Ewig, J Respir Crit Care Med 1999

  47. Clinical Impact of Pneumococcal Resistance in CAP patients • Aspa, et al. CID 2004 • Prospective, multi-center obs study of 638 patients with CAP due to S pneumo in Spain • Isolates: 10% PCN-R, 26% PCN-I • Morbidity: DIC, empyema & bacteremia more common with PCN-S isolates • Mortality: 18% (PCN-R) vs. 18% (PCN-I) vs. 12% (PCN-S), p=.054 (underpowered) • Song, et al. CID 2004. Asia, 233 patients. • No difference in mortality but underpowered

  48. Clinical Impact of Pneumococcal Resistance in Bacteremic patients • Yu, et al. CID 2003 • Prospective, international, multi-center study of 844 bacteremic patients • PCN resistance: 9.6%; 14 d mortality rate 16.9% • Overall, persons with PCN resistant S. pneumo who received monotherapy with ‘the wrong’ antibiotic died at same rate as those who received ‘the right’ antibiotic • Exception: Cefuroxime (standard dosing does not achieve levels above MIC) • 65% deaths occurred w/i 3 days of BCx

  49. Macrolide Resistant Pneumococci • Mechanisms of resistance: • Efflux pump • Ribosomal alteration- prevents macrolide binding to ribosome • Macrolide failures in CAP caused by S. pneumo resistance • Associated with breakthrough bacteremia • Not recommended as monotherapy in bacteremic patients Lonks, CID 2002

  50. Fluoroquinolone resistant pneumococcus • In US: resistance to FQ low but reported • In Canada and Spain: resistance with FQ use • Likelihood of FQ resistance increases with prior FQ exposure in past year • Reports of patients on FQ who have FQ resistant pneumococcus show increased morbidity and mortality • Resistance may develop during treatment • Some guidelines recommend FQ as first line agent due to low resistance rates Chen, NEJM 1999

More Related